HK1130066A1 - Antibody glycosylation in the variable region - Google Patents
Antibody glycosylation in the variable regionInfo
- Publication number
- HK1130066A1 HK1130066A1 HK09106521.6A HK09106521A HK1130066A1 HK 1130066 A1 HK1130066 A1 HK 1130066A1 HK 09106521 A HK09106521 A HK 09106521A HK 1130066 A1 HK1130066 A1 HK 1130066A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- variable region
- antibody glycosylation
- glycosylation
- antibody
- variable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05027090 | 2005-12-12 | ||
PCT/EP2006/011914 WO2007068429A1 (en) | 2005-12-12 | 2006-12-11 | Antibodies against amyloid beta 4 with glycosylated in the variable region |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1130066A1 true HK1130066A1 (en) | 2009-12-18 |
Family
ID=37745986
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09106521.6A HK1130066A1 (en) | 2005-12-12 | 2009-07-17 | Antibody glycosylation in the variable region |
HK13103092.6A HK1176075A1 (en) | 2005-12-12 | 2009-07-17 | Antibody glycosylation in the variable region |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK13103092.6A HK1176075A1 (en) | 2005-12-12 | 2009-07-17 | Antibody glycosylation in the variable region |
Country Status (34)
Country | Link |
---|---|
US (2) | US8906370B2 (xx) |
EP (2) | EP1960428B1 (xx) |
JP (1) | JP5145241B2 (xx) |
KR (2) | KR101401159B1 (xx) |
CN (2) | CN101351476B (xx) |
AR (1) | AR057233A1 (xx) |
AT (1) | ATE517923T1 (xx) |
AU (1) | AU2006326301B2 (xx) |
BR (1) | BRPI0619605B8 (xx) |
CA (1) | CA2632828C (xx) |
CR (1) | CR10000A (xx) |
CY (1) | CY1114783T1 (xx) |
DK (1) | DK1960428T3 (xx) |
DO (1) | DOP2006000278A (xx) |
EC (1) | ECSP088524A (xx) |
ES (1) | ES2368591T3 (xx) |
HK (2) | HK1130066A1 (xx) |
IL (1) | IL191004A (xx) |
JO (1) | JO2824B1 (xx) |
MA (1) | MA30038B1 (xx) |
MY (1) | MY155286A (xx) |
NO (1) | NO346105B1 (xx) |
NZ (1) | NZ568241A (xx) |
PE (3) | PE20071002A1 (xx) |
PL (1) | PL1960428T3 (xx) |
PT (1) | PT1960428E (xx) |
RS (1) | RS52004B (xx) |
RU (1) | RU2438706C2 (xx) |
SI (1) | SI1960428T1 (xx) |
TW (1) | TWI382990B (xx) |
UA (1) | UA99097C2 (xx) |
UY (1) | UY30003A1 (xx) |
WO (1) | WO2007068429A1 (xx) |
ZA (1) | ZA200805038B (xx) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR038568A1 (es) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
RU2442793C2 (ru) | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ |
KR101906161B1 (ko) | 2005-11-30 | 2018-10-11 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
AR057233A1 (es) * | 2005-12-12 | 2007-11-21 | Hoffmann La Roche | Glicosilacion en la region variable |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
CN101553504A (zh) * | 2006-12-11 | 2009-10-07 | 豪夫迈·罗氏有限公司 | Aβ抗体胃肠外制剂 |
US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
BRPI0813963A2 (pt) | 2007-06-29 | 2015-01-06 | Hoffmann La Roche | Mutante de cadeia pesada que leva a uma melhor produção de imunoglobulina |
EP2527367A1 (en) * | 2007-08-20 | 2012-11-28 | Glaxo Group Limited | Production method |
CA2701793C (en) | 2007-10-05 | 2017-04-25 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
EP2234600B1 (en) * | 2007-12-21 | 2014-08-20 | F. Hoffmann-La Roche AG | Antibody formulation |
ES2458541T3 (es) * | 2008-05-02 | 2014-05-06 | Seattle Genetics, Inc. | Métodos y composiciones para elaborar anticuerpos y derivados de anticuerpos con fucosilación del núcleo reducida |
US20120282654A1 (en) * | 2009-04-29 | 2012-11-08 | Schering Corporation | Antibody purification |
EP2519537A4 (en) * | 2009-12-29 | 2013-07-10 | Reddys Lab Ltd Dr | CLEANING PROTEINS |
KR20130010114A (ko) | 2010-03-03 | 2013-01-25 | 베링거 인겔하임 인터내셔날 게엠베하 | 바이파라토픽 a-베타 결합 폴리펩타이드 |
ES2684475T3 (es) | 2010-04-15 | 2018-10-03 | Abbvie Inc. | Proteínas que se unen a beta amiloide |
WO2012016173A2 (en) | 2010-07-30 | 2012-02-02 | Ac Immune S.A. | Safe and functional humanized antibodies |
US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US20140302532A1 (en) | 2011-04-12 | 2014-10-09 | Quanterix Corporation | Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury |
SG11201401360XA (en) * | 2011-10-25 | 2014-05-29 | Onclave Therapeutics Ltd | Antibody formulations and methods |
WO2013081946A1 (en) * | 2011-12-02 | 2013-06-06 | Plaxgen, Inc. | Plaque array method and compositions for forming and detecting plaques |
RS54644B1 (en) | 2012-03-08 | 2016-08-31 | F. Hoffmann-La Roche Ag | ABET ANTIBODY FORMULATION |
CA2879496C (en) * | 2012-08-29 | 2024-01-09 | F. Hoffmann-La Roche Ag | Blood brain barrier shuttle |
CN102998454A (zh) * | 2012-12-11 | 2013-03-27 | 华中师范大学 | 一种检测生物体内邻苯二甲酸二丁酯相对含量的方法 |
US9587022B2 (en) | 2012-12-18 | 2017-03-07 | The Rockefeller University | Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity |
TWI630215B (zh) * | 2012-12-18 | 2018-07-21 | 美國洛克菲勒大學 | 用於hiv預防及治療的醣修飾抗cd4抗體 |
AR094780A1 (es) | 2013-02-13 | 2015-08-26 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | ANTICUERPOS ANTI-TNF-a ALTAMENTE GALACTOSILADOS Y SUS USOS |
JP6169885B2 (ja) | 2013-05-07 | 2017-07-26 | 株式会社日立製作所 | 精製装置及び精製方法 |
WO2015038884A2 (en) | 2013-09-13 | 2015-03-19 | Genentech, Inc. | Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products |
NZ756750A (en) | 2013-09-13 | 2022-05-27 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
WO2015075942A1 (ja) | 2013-11-22 | 2015-05-28 | 国立大学法人 東京大学 | 薬剤送達用のキャリア、コンジュゲートおよびこれらを含んでなる組成物並びにこれらの投与方法 |
JP6744856B2 (ja) | 2014-04-08 | 2020-08-19 | プロセナ・バイオサイエンシズ・リミテッド | α−シヌクレインを認識する抗体を含む血液脳関門シャトル |
WO2015165961A1 (en) | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
DK3313879T3 (da) | 2015-06-24 | 2022-03-14 | Hoffmann La Roche | Anti-transferrinreceptor-antistoffer med tilpasset affinitet |
WO2017032686A1 (en) * | 2015-08-21 | 2017-03-02 | F. Hoffmann-La Roche Ag | Method for the reduction of host cell proteins in affinity chromatography |
KR20180054864A (ko) | 2015-10-02 | 2018-05-24 | 에프. 호프만-라 로슈 아게 | 이중특이성 항-인간 cd20/인간 트랜스페린 수용체 항체 및 사용 방법 |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
HUE057085T2 (hu) * | 2015-10-16 | 2022-04-28 | Hoffmann La Roche | Egy rendszer mûködtetésére szolgáló eljárás és egy rendszer |
WO2017079833A1 (en) | 2015-11-09 | 2017-05-18 | The University Of British Columbia | Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto |
EP3374379A4 (en) | 2015-11-09 | 2019-05-15 | The University Of British Columbia | N-TERMINAL EPITOPES IN BETA-AMYLOID AND CONFORMATIONALLY SELECTIVE ANTIBODIES THEREOF |
US10759837B2 (en) | 2015-11-09 | 2020-09-01 | The University Of British Columbia | Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide |
US10792477B2 (en) * | 2016-02-08 | 2020-10-06 | Orbusneich Medical Pte. Ltd. | Drug eluting balloon |
WO2017153848A1 (en) * | 2016-03-10 | 2017-09-14 | Genomic Vision | Method of curvilinear signal detection and analysis and associated platform |
WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
TWI735600B (zh) | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗-N3pGlu類澱粉β肽抗體及其用途 |
US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
AU2018277333B2 (en) * | 2017-05-30 | 2021-09-16 | Morinaga Milk Industry Co., Ltd. | Composition for improving brain function |
EP3574020B1 (en) | 2017-07-18 | 2024-05-15 | The University of British Columbia | Antibodies to amyloid beta |
CN108048477A (zh) * | 2017-12-15 | 2018-05-18 | 南京理工大学 | 基于大肠杆菌表达***的制备多肽的方法 |
EP3778875A1 (en) | 2019-08-14 | 2021-02-17 | MaxiVax SA | Immortalized myoblast cell lines and uses thereof |
JP2023535024A (ja) | 2020-07-23 | 2023-08-15 | オター プロシーナ リミテッド | 抗aベータ抗体 |
EP4244248A1 (en) | 2020-11-16 | 2023-09-20 | F. Hoffmann-La Roche AG | Fab high mannose glycoforms |
TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
CN114591429B (zh) * | 2022-05-07 | 2022-08-09 | 北京第一生物化学药业有限公司 | 结合β-淀粉样蛋白的抗体及其用途 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666829A (en) | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5811310A (en) | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
CA1339014C (en) | 1987-10-08 | 1997-03-25 | Ronald E. Majocha | Antibodies to a4 amyloid peptide |
JP2780507B2 (ja) * | 1991-03-29 | 1998-07-30 | 松下電器産業株式会社 | 内燃機関用フィルタ再生装置 |
US5955317A (en) * | 1993-01-25 | 1999-09-21 | Takeda Chemical Industries, Ltd. | Antibodies to β-amyloids or their derivatives and use thereof |
EP1308461A3 (en) | 1993-01-25 | 2004-02-11 | Takeda Chemical Industries, Ltd. | Antibodies to beta-amyloids or their derivatives and use thereof |
US5443953A (en) * | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
GB9416007D0 (en) * | 1994-08-08 | 1994-09-28 | Erba Carlo Spa | Anthracyclinone derivatives |
US5688651A (en) * | 1994-12-16 | 1997-11-18 | Ramot University Authority For Applied Research And Development Ltd. | Prevention of protein aggregation |
EP0838033A1 (en) * | 1995-06-06 | 1998-04-29 | Stemcell Therapeutics L.L.C. | GLYCOPROTEIN gp105 ON BL3 HEMATOPOIETIC STEM CELLS |
PT859841E (pt) | 1995-08-18 | 2002-11-29 | Morphosys Ag | Bibliotecas de proteinas/ (poli) peptidos |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
NZ514414A (en) * | 1999-03-04 | 2004-02-27 | Praecis Pharm Inc | Modulators of beta-amyloid peptide aggregation comprising D-amino acids |
AU780474B2 (en) | 1999-06-16 | 2005-03-24 | Boston Biomedical Research Institute Incorporated | Immunological control of beta-amyloid levels in vivo |
AU6722300A (en) | 1999-08-31 | 2001-03-26 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders |
NZ540564A (en) | 1999-11-29 | 2007-04-27 | Neurochem Int Ltd | Vaccine for the prevention and treatment of Alzheimer's and amyloid related diseases |
US20020094335A1 (en) | 1999-11-29 | 2002-07-18 | Robert Chalifour | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
EP1125905A1 (en) | 2000-02-16 | 2001-08-22 | Pepscan Systems B.V. | Segment synthesis |
PL210157B1 (pl) | 2000-02-24 | 2011-12-30 | Lilly Co Eli | Humanizowane przeciwciało lub jego fragment, kwas polinukleinowy, wektor ekspresyjny do ekspresji przeciwciała lub jego fragmentu, komórka transfekowana wektorem ekspresyjnym, kompozycja farmaceutyczna i zastosowanie humanizowanego przeciwciała lub jego fragmentu do leczenia choroby Alzheimera |
CA2313828A1 (en) | 2000-08-01 | 2002-02-01 | Institut De Recherches Cliniques De Montreal/Ircm | Post-translational processing of .beta.-secretase (bace): the pro-and transmembrane/cytosolic domains affect its cellular activity and amyloid a.beta. production |
PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
EP1379283B1 (en) | 2000-12-19 | 2008-02-13 | Palatin Technologies, Inc. | Identification of target-specific folding sites in peptides and proteins |
ATE420114T1 (de) | 2001-04-30 | 2009-01-15 | Lilly Co Eli | Humanisierte antikörper die das beta-amyloid peptid erkennen& x9; |
AU2002257162A1 (en) | 2001-04-30 | 2002-11-11 | Eli Lilly And Company | Humanized antibodies |
CA2451998A1 (en) * | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | Anti-a.beta. antibodies |
EP1944040B1 (en) * | 2001-08-17 | 2012-08-01 | Washington University | Assay method for Alzheimer's disease |
AR038568A1 (es) * | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
MY139983A (en) * | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
PL377769A1 (pl) | 2002-10-09 | 2006-02-20 | Rinat Neuroscience Corp. | Sposób leczenia choroby Alzheimera z zastosowaniem przeciwciał skierowanych przeciw peptydowi beta amyloidu i ich kompozycje |
DE10303974A1 (de) * | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
AR057233A1 (es) * | 2005-12-12 | 2007-11-21 | Hoffmann La Roche | Glicosilacion en la region variable |
CN101553504A (zh) * | 2006-12-11 | 2009-10-07 | 豪夫迈·罗氏有限公司 | Aβ抗体胃肠外制剂 |
-
2006
- 2006-12-11 AR ARP060105433A patent/AR057233A1/es unknown
- 2006-12-11 RU RU2008128138/10A patent/RU2438706C2/ru active
- 2006-12-11 PT PT06829502T patent/PT1960428E/pt unknown
- 2006-12-11 TW TW095146304A patent/TWI382990B/zh active
- 2006-12-11 DO DO2006000278A patent/DOP2006000278A/es unknown
- 2006-12-11 PE PE2006001587A patent/PE20071002A1/es not_active Application Discontinuation
- 2006-12-11 EP EP06829502A patent/EP1960428B1/en active Active
- 2006-12-11 NO NO20082874A patent/NO346105B1/no unknown
- 2006-12-11 MY MYPI20081349A patent/MY155286A/en unknown
- 2006-12-11 JO JO2006444A patent/JO2824B1/en active
- 2006-12-11 JP JP2008543748A patent/JP5145241B2/ja active Active
- 2006-12-11 CA CA2632828A patent/CA2632828C/en active Active
- 2006-12-11 EP EP11169488A patent/EP2377886A1/en not_active Withdrawn
- 2006-12-11 PL PL06829502T patent/PL1960428T3/pl unknown
- 2006-12-11 CN CN2006800463079A patent/CN101351476B/zh active Active
- 2006-12-11 UA UAA200808791A patent/UA99097C2/ru unknown
- 2006-12-11 RS RS20110401A patent/RS52004B/en unknown
- 2006-12-11 US US12/086,309 patent/US8906370B2/en active Active
- 2006-12-11 SI SI200631096T patent/SI1960428T1/sl unknown
- 2006-12-11 CN CN201210137369.8A patent/CN102659943B/zh active Active
- 2006-12-11 AU AU2006326301A patent/AU2006326301B2/en active Active
- 2006-12-11 KR KR1020127010552A patent/KR101401159B1/ko active IP Right Grant
- 2006-12-11 UY UY30003A patent/UY30003A1/es unknown
- 2006-12-11 KR KR1020087012289A patent/KR20080077132A/ko active Search and Examination
- 2006-12-11 AT AT06829502T patent/ATE517923T1/de active
- 2006-12-11 NZ NZ568241A patent/NZ568241A/en unknown
- 2006-12-11 PE PE2010000560A patent/PE20100748A1/es active IP Right Grant
- 2006-12-11 DK DK06829502.1T patent/DK1960428T3/da active
- 2006-12-11 BR BRPI0619605A patent/BRPI0619605B8/pt active IP Right Grant
- 2006-12-11 WO PCT/EP2006/011914 patent/WO2007068429A1/en active Application Filing
- 2006-12-11 PE PE2010000354A patent/PE20100684A1/es not_active Application Discontinuation
- 2006-12-11 ES ES06829502T patent/ES2368591T3/es active Active
-
2008
- 2008-04-27 IL IL191004A patent/IL191004A/en active IP Right Grant
- 2008-05-20 CR CR10000A patent/CR10000A/es unknown
- 2008-06-09 MA MA31014A patent/MA30038B1/fr unknown
- 2008-06-10 ZA ZA200805038A patent/ZA200805038B/xx unknown
- 2008-06-10 EC EC2008008524A patent/ECSP088524A/es unknown
-
2009
- 2009-07-17 HK HK09106521.6A patent/HK1130066A1/xx unknown
- 2009-07-17 HK HK13103092.6A patent/HK1176075A1/xx unknown
-
2011
- 2011-09-16 CY CY20111100899T patent/CY1114783T1/el unknown
-
2014
- 2014-11-07 US US14/536,262 patent/US9272031B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1130066A1 (en) | Antibody glycosylation in the variable region | |
HK1218126A1 (zh) | 抗體 | |
IL187106A (en) | Sclerostin binds antibody | |
IL190472A0 (en) | Anti-glypican-3 antibody | |
IL185366A0 (en) | Antibody | |
IL187316A0 (en) | Anti-interleukin 2 antibodies | |
IL186500A0 (en) | Protein glycosylation | |
GB0502992D0 (en) | The ballcaster | |
GB0523899D0 (en) | The one | |
GB0511610D0 (en) | The motor-roll-off | |
PL376079A1 (pl) | Piec akumulacyjny obiektu | |
GB0516424D0 (en) | Improvement in the lamp | |
GB0526162D0 (en) | The gift | |
GB0500400D0 (en) | Antibody | |
GB0506202D0 (en) | The uni-tray | |
GB0502412D0 (en) | The sproke | |
GB0511718D0 (en) | The texer | |
GB0511228D0 (en) | The cat-lock | |
GB0524595D0 (en) | The guillospade | |
GB0500175D0 (en) | The astrocelesphere | |
GB0517209D0 (en) | The wayfinder | |
GB0519318D0 (en) | The wheelbox | |
GB0521054D0 (en) | The chew-it-bar | |
GB0521243D0 (en) | The grapler |